
Friday, May 31, 2024 8:41:13 PM
Recent ITRM News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/03/2025 08:16:04 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/03/2025 08:15:09 PM
- Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 07/02/2025 08:30:00 PM
- Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth • GlobeNewswire Inc. • 06/30/2025 11:00:00 AM
- Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence • GlobeNewswire Inc. • 06/25/2025 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2025 11:15:25 AM
- Iterum Therapeutics Announces Partnership for Commercialization Services • GlobeNewswire Inc. • 06/11/2025 11:00:00 AM
- Iterum Therapeutics Announces Extension of Term of Promissory Note • GlobeNewswire Inc. • 05/19/2025 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2025 11:30:25 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2025 11:15:09 AM
- Iterum Therapeutics Reports First Quarter 2025 Financial Results • GlobeNewswire Inc. • 05/13/2025 11:00:00 AM
- Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025 • GlobeNewswire Inc. • 05/06/2025 11:00:00 AM
- Iterum Therapeutics Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares • GlobeNewswire Inc. • 04/30/2025 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2025 01:16:27 AM
- Iterum Therapeutics Announces $5 Million Registered Direct Offering of Ordinary Shares • GlobeNewswire Inc. • 04/29/2025 12:00:00 PM
- Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics • GlobeNewswire Inc. • 04/14/2025 12:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2025 12:00:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/10/2025 12:35:07 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/20/2025 05:15:09 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2025 09:49:20 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/07/2025 09:33:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/07/2025 12:30:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2025 12:15:07 PM
- Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results • GlobeNewswire Inc. • 02/07/2025 12:00:00 PM
- Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025 • GlobeNewswire Inc. • 01/31/2025 01:00:00 PM
Glidelogic Corp. Announces Release of First AI-Generated Novel "The Thirteenth Proposal" • GDLG • Jul 11, 2025 12:20 PM
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM
Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment • FITY • Jul 8, 2025 8:30 AM
Avant Technologies and Partner, Ainnova, Launch Transformative Preventative Care Model for Chronic Patients Across Latin America • AVAI • Jul 8, 2025 8:00 AM